JAMA Oncology
Comment & Response
April 4, 2024
MotokoÌýTachihara,ÌýMD, PhD; KayokoÌýTsujino,ÌýMD, PhD
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0234
JAMA Oncology
Original Investigation
December 21, 2023
YoshimasaÌýShiraishi,ÌýMD; JunjiÌýKishimoto,ÌýMA; ShunichiÌýSugawara,ÌýMD, PhD; HideakiÌýMizutani,ÌýMD, PhD; HarukoÌýDaga,ÌýMD, PhD; KoichiÌýAzuma,ÌýMD, PhD; HirotakaÌýMatsumoto,ÌýMD, PhD; OsamuÌýHataji,ÌýMD, PhD; KazumiÌýNishino,ÌýMD, PhD; MasahideÌýMori,ÌýMD, PhD; TakehitoÌýShukuya,ÌýMD, PhD; HaruhiroÌýSaito,ÌýMD, PhD; MotokoÌýTachihara,ÌýMD, PhD; HidetoshiÌýHayashi,ÌýMD, PhD; AsukaÌýTsuya,ÌýMD, PhD; KazushigeÌýWakuda,ÌýMD, PhD; NorikoÌýYanagitani,ÌýMD, PhD; TomohiroÌýSakamoto,ÌýMD, PhD; SatoruÌýMiura,ÌýMD, PhD; AkitoÌýHata,ÌýMD; MorihitoÌýOkada,ÌýMD, PhD; ToshiyukiÌýKozuki,ÌýMD, PhD; YukiÌýSato,ÌýMD; TaishiÌýHarada,ÌýMD, PhD; KoichiÌýTakayama,ÌýMD, PhD; NobuyukiÌýYamamoto,ÌýMD, PhD; KazuhikoÌýNakagawa,ÌýMD, PhD; IsamuÌýOkamoto,ÌýMD, PhD
JAMA Oncol. 2023; 10(3):315-324. 10.1001/jamaoncol.2023.5258
This randomized clinical trial compares progression-free survival using treatment with atezolizumab plus carboplatin with pemetrexed vs atezolizumab, carboplatin with pemetrexed, and bevacizumab in patients with non–small cell lung cancer.
JAMA Oncology
Original Investigation
September 7, 2023
MotokoÌýTachihara,ÌýMD, PhD; KayokoÌýTsujino,ÌýMD, PhD; TakeakiÌýIshihara,ÌýMD, PhD; HidetoshiÌýHayashi,ÌýMD, PhD; YukiÌýSato,ÌýMD; TakayasuÌýKurata,ÌýMD, PhD; ShunichiÌýSugawara,ÌýMD, PhD; YoshimasaÌýShiraishi,ÌýMD; ShunsukeÌýTeraoka,ÌýMD; KoichiÌýAzuma,ÌýMD, PhD; HarukoÌýDaga,ÌýMD, PhD; MasafumiÌýYamaguchi,ÌýMD, PhD; TakeshiÌýKodaira,ÌýMD, PhD; MiyakoÌýSatouchi,ÌýMD, PhD; MototsuguÌýShimokawa,ÌýPhD; NobuyukiÌýYamamoto,ÌýMD, PhD; KazuhikoÌýNakagawa,ÌýMD, PhD; West Japan Oncology Group (WJOG)
JAMA Oncol. 2023; 9(11):1505-1513. 10.1001/jamaoncol.2023.3309
This single-arm, phase 2 nonrandomized controlled trial assesses the efficacy and safety of durvalumab with concurrent radiotherapy followed by durvalumab for treatment of patients with unresectable, locally advanced non–small cell lung cancer.
JAMA Oncology
Brief Report
March 18, 2021
YoshitakaÌýZenke,ÌýMD; MasahiroÌýTsuboi,ÌýMD; YasutakaÌýChiba,ÌýPhD; KayokoÌýTsujino,ÌýMD; MiyakoÌýSatouchi,ÌýMD; KenjiÌýSawa,ÌýMD; JunichiÌýShimizu,ÌýMD; HarukoÌýDaga,ÌýMD; DaichiÌýFujimoto,ÌýMD; MasahideÌýMori,ÌýMD; TakuyaÌýAoki,ÌýMD; ToshiyukiÌýSawa,ÌýMD; ShotaÌýOmori,ÌýMD; HideoÌýSaka,ÌýMD; YasuoÌýIwamoto,ÌýMD; MotoyasuÌýOkuno,ÌýMD; TomonoriÌýHirashima,ÌýMD; KosukeÌýKashiwabara,ÌýMD; MotokoÌýTachihara,ÌýMD; NobuyukiÌýYmamoto,ÌýMD; KazuhikoÌýNakagawa,ÌýMD
free access
JAMA Oncol. 2021; 7(6):904-909. 10.1001/jamaoncol.2021.0113
This randomized clinical trial examines survival rates and late toxic effects 10 years after Japanese patients with stage III non–small-cell lung cancer were treated with curative chemoradiotherapy.
JAMA Oncology
Original Investigation
January 7, 2021
HiroakiÌýAkamatsu,ÌýMD, PhD; YukihiroÌýToi,ÌýMD; HidetoshiÌýHayashi,ÌýMD, PhD; DaichiÌýFujimoto,ÌýMD; MotokoÌýTachihara,ÌýMD, PhD; NaokiÌýFuruya,ÌýMD, PhD; SakikoÌýOtani,ÌýMD, PhD; JunichiÌýShimizu,ÌýMD, PhD; NobuyukiÌýKatakami,ÌýMD, PhD; KoichiÌýAzuma,ÌýMD, PhD; NaokoÌýMiura,ÌýMD, PhD; KazumiÌýNishino,ÌýMD, PhD; SatoshiÌýHara,ÌýMD; ShunsukeÌýTeraoka,ÌýMD; SatoshiÌýMorita,ÌýPhD; KazuhikoÌýNakagawa,ÌýMD, PhD; NobuyukiÌýYamamoto,ÌýMD, PhD
open access
JAMA Oncol. 2021; 7(3):386-394. 10.1001/jamaoncol.2020.6758
This randomized clinical trial assesses the efficacy and safety of osimertinib plus bevacizumab vs osimertinib alone in patients with EGFR T790M–mutated lung adenocarcinoma.